| 000 | 01040 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250514010647.0 | ||
| 264 | 0 | _c20010920 | |
| 008 | 200109s 0 0 eng d | ||
| 022 | _a1170-7690 | ||
| 024 | 7 |
_a10.2165/00019053-200119070-00003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRubenstein, L M | |
| 245 | 0 | 0 |
_aEconomic and health-related quality of life considerations of new therapies in Parkinson's disease. _h[electronic resource] |
| 260 |
_bPharmacoEconomics _c2001 |
||
| 300 |
_a729-52 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aCost of Illness |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHealth Status |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aQuality of Life |
| 700 | 1 | _aDeLeo, A | |
| 700 | 1 | _aChrischilles, E A | |
| 773 | 0 |
_tPharmacoEconomics _gvol. 19 _gno. 7 _gp. 729-52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00019053-200119070-00003 _zAvailable from publisher's website |
| 999 |
_c11471558 _d11471558 |
||